Momenta Pharmaceuticals Inc. (MNTA): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report

Cambridge, MA-based Momenta Pharmaceuticals, Inc. is a biotechnology company focused on designing products on the basis of a complex systems analysis platform, analyzing data to assess the biological function of these products and developing manufacturing processes for their production.

The company operates in three areas Complex Generics, Biosimilars and Novel Drugs.

Momenta's only approved product, Enoxaparin Sodium Injection (generic version of Sanofi's Lovenox), was developed in collaboration with Sandoz and received approval in Jul 2010. Meanwhile, the company is collaborating with Sandoz to develop M356 (generic version of Teva's Copaxone). The company is also looking forward to develop and commercialize two biosimilars, M923 (biosimilar version of AbbVie's Humira) and M834, for autoimmune and inflammatory diseases, under a global collaboration and license agreement with Baxter International. However, Momenta's proprietary candidate necuparanib, which is being evaluated as a first-line treatment of metastatic pancreatic cancer in combination with Abraxane and Gemzar, is the most advanced candidate in the company's pipeline.

Momenta generated revenues of $35.5 million in fiscal 2013 (ended Dec 2013), down 44.5% from the year-ago period.